Earnings

ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate

Aug 10, 2026 · 04:25 PM ET· updated 1h ago

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the

Why It Matters

ProKidney lost a tiny bit more money per share than experts predicted, though sales grew slightly better than expected. When a company misses on losses, it hints the business is spending more than planned, which is worth watching even if sales are good.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

PROK1.66

+0.02 (+1.22%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.